WIRobotics signs Ottobock to sell its WIM S wearable robot in the US and Canada
South Korean wearable-robot maker WIRobotics said in a press release on Nov 16 that its US subsidiary signed a distribution and sales agreement with Otto Bock HealthCare LP on Oct 15. Ottobock will distribute the WIM S walking-assist robot in the United States and Canada, with online sales in the US already open and trials at selected orthotic and prosthetic clinics.
WIM has passed 4,000 units in cumulative sales in its third year on the market, the company said.
WIRobotics, the Korean maker of the WIM wearable walking-assist robot, said in a press release distributed on PR Newswire on Nov 16 that its US subsidiary WIRobotics USA Inc. signed a distribution and sales agreement with Otto Bock HealthCare LP on Oct 15. Under the deal WIRobotics USA supplies the WIM S and Ottobock acts as distribution partner in the United States and Canada. Hankyung and Seoul Economic Daily carried the announcement in Korean on Nov 17.
The launch starts in the US. Buyers can already order the WIM S through Ottobock's direct-to-consumer online platform and WIRobotics USA's online store, and will be able to try the robot at selected orthotic and prosthetic (O&P) clinics. The companies will consider more US trial locations and sales in Canada depending on customer response. They plan to work together on market development, brand building, product training and after-sales service, with WIRobotics USA handling local training and service. No financial terms or volume targets were disclosed.
Why the distributor matters more than the robot
Ottobock, founded in Germany in 1919, already runs distribution, clinical care and service networks in the United States and Canada, according to the release. For a startup selling a consumer mobility device abroad, that clinic network solves the hardest part of the job: fitting, training and repair close to the user. The release says WIM, now in its third year of commercial sales, has passed 4,000 units cumulatively and is sold in Europe, China and Japan as well as Korea.
The agreement covers the consumer WIM S only. The companies see room to extend it to WIM Medi, the medical version WIRobotics is developing, but entry into US and Canadian medical and rehabilitation channels would require regulatory authorisation and a separate agreement, the release says.
- Contract parties
- WIRobotics USA Inc. and Otto Bock HealthCare LP
- Product
- WIM S (consumer wearable walking-assist robot)
- Sales channels
- Ottobock direct-to-consumer platform, WIRobotics USA online store
- Trial points
- Selected US orthotic and prosthetic clinics
- Next steps named
- More US locations, Canada, possibly WIM Medi after regulatory authorisation and a separate agreement
- Financial terms
- Not disclosed
WIRobotics press release on PR Newswire, Nov 16, 2026.
As of Nov 17, 2026
The release came 32 days after the signing (MEKAWIRE calc.). WIRobotics raised KRW 95 billion, about USD 68 million, in a Series B in May 2026, according to the same release; MEKAWIRE covered that round and compared the company with Angel Robotics and Hurotics in its Korean wearable robot comparison.
MEKAWIRE analysis
The deal buys WIRobotics a sales and service channel in North America without building one, but it starts as a consumer product sold online, not as a reimbursed medical device.
The counter-argument is that the consumer route is the faster one: it avoids the wait for regulatory authorisation and lets Ottobock's clinics test demand before the medical version arrives. The risk is that 4,000 units over almost three years is a small base, and the release gives no target for North America.
What to watch: US sales uptake now that online sales are open, the first clinic locations, any Canadian launch, and a regulatory filing for WIM Medi in the US. Company pages: WIRobotics, Ottobock.
- United States and Canada (US first)
- Oct 15, 2026, announced Nov 16
- 1919, Germany
- KRW 95bn, about USD 68m
- more than 4,000 units (company figure)
- 32 days (MEKAWIRE calc.)
